Sun-Novo(688621) 华安证券·2025-04-13 05:23Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a revenue of 1.078 billion yuan in 2024, representing a year-on-year growth of 15.70%, while the net profit attributable to shareholders decreased by 3.98% to 177 million yuan. The fourth quarter saw a revenue decline of 32.62% year-on-year, with a net profit of -30 million yuan, down 321.33% [5][7] - New orders continue to grow, with a total of 1.786 billion yuan in new orders signed in 2024, an increase of 18.74% year-on-year, and a cumulative backlog of 3.273 billion yuan, up 27.57% [5] - The company has significantly increased its R&D investment, with R&D expenses reaching 172 million yuan in 2024, a 39.02% increase, accounting for 15.94% of revenue. The company has over 430 R&D projects, with more than 89 new self-research projects initiated [6] Summary by Sections Financial Performance - In 2024, the company achieved a revenue of 1.078 billion yuan, with a year-on-year growth of 15.70%. The net profit attributable to shareholders was 177 million yuan, down 3.98%. The fourth quarter revenue was 162 million yuan, a decline of 32.62%, and the net profit was -30 million yuan, a decrease of 321.33% [5][10] Business Segments - The revenue from pharmaceutical research services in 2024 was 559 million yuan, down 1.74%, with a gross margin of 61.37%. The clinical trial and bioanalysis business generated 512 million yuan, up 41.19%, with a gross margin of 31.17%. Revenue from equity sharing was 6.5336 million yuan [5] R&D Investment - The company has increased its R&D expenses to 172 million yuan in 2024, a 39.02% increase, representing 15.94% of total revenue. The company has over 430 R&D projects, with significant progress in clinical trials for various indications [6] Future Projections - Revenue projections for 2025 to 2027 are 1.290 billion yuan, 1.513 billion yuan, and 1.781 billion yuan, with year-on-year growth rates of 19.6%, 17.3%, and 17.7% respectively. Net profit projections for the same period are 213 million yuan, 256 million yuan, and 304 million yuan, with growth rates of 20.3%, 20.0%, and 18.7% respectively [7][10]